Giarmoukakis Athanassios K, Blazaki Styliani V, Bontzos Georgios C, Plaka Argyro D, Seliniotakis Konstantinos N, Ioannidi Larissa D, Tsilimbaris Miltiadis K
Department of Ophthalmology, University Hospital of Heraklion, Heraklion, Greece.
Ther Clin Risk Manag. 2020 Nov 6;16:1067-1074. doi: 10.2147/TCRM.S271184. eCollection 2020.
To assess the effect of twice-daily nepafenac ophthalmic suspension 0.3% on postoperative cystoid-macular-edema (CME).
In this prospective, clinic-based, non-randomized case-series, 21 patients (21 eyes) were enrolled with either acute or chronic postoperative CME after cataract extraction. Patients were treated with twice-daily nepafenac 0.3% drops, and followed for at least a 4-month period. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT)-derived central retinal thickness (CRT) were measured.
From 21 patients, eight presented with acute postoperative CME and 13 with chronic CME. Mean follow-up was 4.82±1.24 months. No adverse events were reported during the study. Baseline BCVA was 0.49±0.36 logMAR and improved to 0.36±0.42 logMAR at the last follow-up visit (<0.005). CRT decreased from 450.40±90.74 μm at baseline to 354.60±81.49 μm (<0.05), following treatment.
Our outcomes strongly suggest that administrating nepafenac 0.3% drops on a twice-daily regimen could be a promising alternative for the management of postoperative CME. Additional studies are necessary to further validate our results.
评估0.3%奈帕芬酸眼用混悬液每日两次给药对术后黄斑囊样水肿（CME）的影响。
在这项前瞻性、基于临床的非随机病例系列研究中，纳入了21例白内障摘除术后出现急性或慢性CME的患者（21只眼）。患者接受0.3%奈帕芬酸滴眼液每日两次治疗，并随访至少4个月。测量最佳矫正视力（BCVA）和光谱域光学相干断层扫描（SD-OCT）得出的中心视网膜厚度（CRT）。
21例患者中，8例出现急性术后CME，13例出现慢性CME。平均随访时间为4.82±1.24个月。研究期间未报告不良事件。基线BCVA为0.49±0.36 logMAR，在最后一次随访时提高至0.36±0.42 logMAR（<0.005）。治疗后，CRT从基线时的450.40±90.74μm降至354.60±81.49μm（<0.05）。
我们的结果强烈表明，每日两次使用0.3%奈帕芬酸滴眼液可能是治疗术后CME的一种有前景的替代方法。需要进一步的研究来进一步验证我们的结果。
